Oviduct-specific glycoprotein is a molecular marker for invasion In endometrial tumorigenesis identified using a relevant mouse model

International Journal of Cancer

Volumn 124, Issue 6, 2009, Pages 1349-1357

  Wang, Hong ^a   Joshi, Ayesha ^a   Iaconis, Lori ^a   Solomon, Garron J ^a   Zhaoying, Xiang ^a   Verhage, Harold G ^b   Douglas, Wayne ^a   Ronnett, Brigitte M ^c   Ellenson, Lora Hedrick ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Endometrial tumorigenesis; Molecular marker of invasive disease; Mouse model

Indexed keywords

GLYCOPROTEIN; MOLECULAR MARKER; OVIDUCT SPECIFIC GLYCOPROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG; MLH1 PROTEIN, MOUSE; NUCLEAR PROTEIN; PRIMER DNA; PTEN PROTEIN, MOUSE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CARCINOGENESIS; CONTROLLED STUDY; DNA ISOLATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; EXPERIMENTAL MODEL; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE INACTIVATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE SPECIFICITY; UNINDEXED SEQUENCE; WILD TYPE; ANIMAL; DISEASE MODEL; ENDOMETRIUM TUMOR; EXON; GENETICS; GENOTYPE; METASTASIS; MOUSE MUTANT; PATHOLOGY; UTERINE TUBE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; DISEASE MODELS, ANIMAL; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; ENDOMETRIAL NEOPLASMS; EXONS; FALLOPIAN TUBES; FEMALE; GENOTYPE; LOSS OF HETEROZYGOSITY; MICE; MICE, KNOCKOUT; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NUCLEAR PROTEINS; PTEN PHOSPHOHYDROLASE; TUMOR MARKERS, BIOLOGICAL;

EID: 60549107725     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24022     Document Type: Article

References (42)

1. Kurrnan RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985;56:403-12.
2. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ, II, Alberts D, Curtin J. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006;106:812-9.
3. Simpkins SB, Peiffer-Schneider S, Mutch DG, Gersell D, Goodfellow PJ. PTEN mutations in endometrial cancers with 10q LOH: additional evidence for the involvement of multiple tumor suppressors. Gynecol Oncol 1998;71:391-5.
4. Kong D, Suzuki A, Zou TT, Sakurada A, Kemp LW, Wakatsuki S, Yokoyama T, Yamakawa H, Furukawa T, Sato M, Ohuchi N, Sato S, et al. PTEN1 Is frequently mutated in primary endometrial carcinomas. Nat Genet 1997;17:143-4.
5. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R, Ellenson LH. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57:3935-40.
6. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, Weng LP, Eng C. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-30.
7. Lu TL, Chang JL, Liang CC, You LR, Chen CM. Tumor spectrum, tumor latency and tumor incidence of the Pten-deficient mice. PLoS ONE 2007;2:e l237.
8. Wang H, Douglas W, Lia M, Edelmann W, Kucherlapati R, Podsypanina K, Parsons R, Ellenson LH, DNA mismatch repair deficiency accelerates endometrial tumorigenesis in Pten heterozygous mice. Am J Pathol 2002;160:1481-6.
9. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R. Mutation of Pten/Mmac 1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999;96:1563-8.
10. Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW. High incidence of breast and endometrial neoplasia resem bling human Cowden syndrome in pten"'"'"" mice. Cancer Res 2000;60:3605-11.
11. Helland A, Borresen-Dale AL, Peltoraaki P, Hektoen M, Kristensen GB, Nesland JM, de la Chapelle A, Lothe RA. Microsatellite instability in cervical and endometrial carcinomas. Int J Cancer 1997;70:499-501.
12. Gurin CC, Federici MG, Kang L, Boyd J. Causes and consequences of microsatellite instability in endometrial carcinoma. Cancer Res. 1999;59:462-6.
13. Levine RL, Cargile CB, Blazes MS, van Rees B, Kurman RJ, Ellenson LH. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res 1998;58:3254-8.
14. Burks RT, Kessis TO, Cho KR, Hedriek L. Microsatellite instability in endometrial carcinoma. Oncogene 1994;9:1163-6.
15. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedriek L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000;88:814-24.
16. Esteller M, Xercavins J, Reventos J. Advances in the molecular genetics of endometrial cancer (Review). Oncol Rep 1999;6:1377-82.
17. Salvesen HB, MacDonald N, Ryan A, Iversen OE, Jacobs IJ, Akslen LA, Das S. Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res 2000;6:3607-13.
18. Pare YR, Hailing KC, Burgart LJ, McDonnell SK, Schaid DJ, Thibodeau SN, Hailing AC. Microsatellite instability and hMLH1/hMSH2 expression in young endometrial carcinoma patients: associations with family history and histopathology, Int J Cancer 2000;86:60-6.
19. Rapisarda JJ, Mavrogianis PA, O'Day-Bowman MB, Fazleabas AT, Verhage HG. Immunological characterization and iramunocytochemical localization of an oviduct-specific glycoprotein in the human. J Clin Endocrinol Metab 1993;76:1483-8.
20. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedriek L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177-85.
21. Hayes MP, Wang H, Espinal-Witter R, Douglas W, Solomon GJ, Baker SJ, Ellenson LH. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 2006;12:5932-5.
22. Risinger JI, Hayes K, Maxwell GL, Carney ME, Dodge RK, Barrett JC, Berchuck A. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 1998;4:3005-10.
23. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J. The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer. Eur J Cancer 1997;33:1572-7.
24. Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S, Hirohashi S. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 1998;58:3526-8.
25. Saegusa M, Hashimura M, Yoshida T, Okayasu I. beta-Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Br J Cancer 2001;84:209-17.
26. Duval A, Hamelin R. Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res 2002;62:2447-54.
27. Vassileva V, Millar A, Briollais L, Chapman W, Bapat B. Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. Cancer Res 2002;62:4095-9.
28. McIver CM, Lloyd JM, Hewett PJ, Hardingham JE. Dipeptidase I: a candidate tumor-specific molecular marker in colorectal carcinoma. Cancer Lett 2004;209:67-74.
29. Bussaglia E, del Rio E, Matias-Guiu X, Prat J. PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. Hum Pathol 2000;31:312-7.
30. Maxwell GL, Risinger JI, Alvarez AA, Barrett JC, Berchuck A. Favorable survival associated with microsatellite instability in endometrioid endometrial cancers. Obstet Gynecol 2001;97:417-22.
31. Kabbarah O, Sotelo AK, Mallon MA, Winkeler EL, Fan MY, Pfeifer JD, Shibata D, Gutmann DH, Goodfellow PJ. Diethylstilbestrol effects and lymphomagenesis in Mlh 1-deficient mice. Int J Cancer 2005;115:666-9.
32. Bassi DE, Lopez De Cicco R, Cenna J, Litwin S, Cukierraan E, Klein-Szanto AJ. PACE4 expression in mouse basal keratinocytes results in basement membrane disruption and acceleration of tumor progression. Cancer Res 2005;65:7310-9.
33. Risinger JI, Maxwell GL, Chandramouli GV, Aprelikova O, Litzi T, Umar A, Berchuck A, Barrett JC. Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling. Cancer Res 2005;65:5031-7.
34. Shedden KA, Kshirsagar MP, Schwartz DR, Wu R, Yu H, Misek DE, Hanash S, Katabuchi H, Ellenson LH, Fearon ER, Cho KR. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clin Cancer Res 2005;11:2123-31.
35. Moreno-Bueno G, Hardisson D, Sanchez C, Sarrio D, Cassia R, Gar-cia-Rostan G, Prat J, Guo M, Herman JG, Matias-Guiu X, Esteller M, Palacios J. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 2002;21:7981-90.
36. Kadam KM, D'souza SJ, Natraj U. Identification of cellular isoform of oviduct-specific glycoprotein: role in oviduct tissue remodeling? Cell Tissue Res 2007;330:545-56.
37. . Abe H, Satoh T, Hoshi H. Primary modulation by oestradiol of the production of an oviduct-specific glycoprotein by the epithelial cells in the oviduct of newborn golden hamsters. J Reprod Fertil 1998;112:157-63.
38. Verhage HG, Mavrogianis PA, Boomsma RA, Schmidt A, Brenner RM, Slayden OV, Jaffe RC. Immunologic and molecular characterization of an estrogen-dependent glycoprotein in the rhesus (Macaca mulatta) oviduct. Biol Reprod 1997;57:525-31.
39. Murray MK. Biosynthesis and Immunocytochemical localization of an estrogen-dependent glycoprotein and associated morphological alterations in the sheep ampulla oviduct. Biol Reprod 1992;47:889-902.
40. Jaffe RC, Arias EB, O'Day-Bowman MB, Donnelly KM, Mavrogianis PA, Verhage HG, Regional distribution and hormonal control of estrogen-dependent oviduct-specific glycoprotein messenger ribonucleic acid in the baboon (Papio anubis). Biol Reprod 1996;55:421-6.
41. Buhi WC, Ashworth CJ, Bazer FW, Alvarez IM. In vitro synthesis of oviductal secretory proteins by estrogen-treated ovariectomized gilts. J Exp Zool 1992;262:426-35.
42. Woo MM, Alkushi A, Verhage HG, Magliocco AM, Leung PC, Gilks CB, Auersperg N. Gain of OOP, an estrogen-regulated oviduct-specific glycoprotein, is associated with the development of endometrial hyperplasia and endometrial cancer. Clin Cancer Res 2004; 10:7958-64.